LICENSING AGREEMENTS AND ACQUISITIONS - Narrative (Details)			1 Months Ended		3 Months Ended		9 Months Ended
	Sep. 29, 2023 USD ($) rate	Jan. 17, 2023 USD ($)	Jul. 31, 2023 USD ($)	Jan. 31, 2023 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Business Acquisition [Line Items]
Other expense, net					$ 60,000,000	$ 4,000,000	$ 0	$ 6,000,000
Interest expense, net					339,000,000	$ 385,000,000	965,000,000	$ 1,157,000,000
Goodwill					11,187,000,000		11,187,000,000		$ 11,547,000,000	$ 12,457,000,000
Bausch + Lomb | Johnson & Johnson Vision, Blink Product Line Acquisition
Business Acquisition [Line Items]
Cash consideration paid, asset acquisition			$ 107,000,000
Bausch + Lomb | XIIDRA® And Certain Other Ophthalmology Assets Acquisition
Business Acquisition [Line Items]
Cash consideration paid	$ 1,750,000,000
Potential future milestone obligations (up to)	750,000,000
Consideration transferred	1,753,000,000
Contingent consideration, liability	$ 3,000,000
Inventory release turnover cycle, favorable contract, term	2 years
Goodwill	$ 23,000,000
Bausch + Lomb | XIIDRA® And Certain Other Ophthalmology Assets Acquisition | Cash Payable Upon the Achievement of Specified Commercialization and Sales Milestones for Certain Pipeline Products
Business Acquisition [Line Items]
Potential future milestone obligations (up to)	475,000,000
Bausch + Lomb | XIIDRA® And Certain Other Ophthalmology Assets Acquisition | Cash Payable Upon the Achievement of Specified Sales Milestones
Business Acquisition [Line Items]
Potential future milestone obligations (up to)	275,000,000
Bausch + Lomb | XIIDRA® And Certain Other Ophthalmology Assets Acquisition | Milestone Payments
Business Acquisition [Line Items]
Contingent consideration, liability	$ 31,000,000
Bausch + Lomb | XIIDRA® And Certain Other Ophthalmology Assets Acquisition | Milestone Payments | Measurement Input, Discount Rate
Business Acquisition [Line Items]
Contingent consideration, liability, discount rate | rate	0.11
Bausch + Lomb | XIIDRA® And Certain Other Ophthalmology Assets Acquisition | Acquisition-Related Transaction Costs
Business Acquisition [Line Items]
Other expense, net					14,000,000		14,000,000
Bausch + Lomb | XIIDRA® And Certain Other Ophthalmology Assets Acquisition | Acquisition-Related Finance Costs
Business Acquisition [Line Items]
Interest expense, net					$ 16,000,000		$ 16,000,000
Bausch + Lomb | AcuFocus, Inc. Acquisition
Business Acquisition [Line Items]
Cash consideration paid				$ 31,000,000
Consideration transferred		$ 35,000,000
Contingent consideration, liability		$ 5,000,000
Purchase price, repayment term		18 months
Intangibles, net		$ 28,000,000
Goodwill		8,000,000
Other assets		9,000,000
Liabilities		$ 6,000,000